AI Analysis
Summary
Agenus is discontinuing a late-stage colorectal cancer study, while Apnimed prepares for an IPO and an ebola vaccine enters human testing; Bristol Myers Squibb received an FDA decision date for an unnamed medicine.
Outcome Details
Agenus abandoning colorectal cancer study; Ebola vaccine began human testing; Bristol Myers medicine received FDA decision date
Importance:4/10
Sentiment:
0.20
clinical_trial_discontinuationvaccine_developmentFDA_decisionIPOcolorectal_cancer
Related Companies
Read the original article
Published by BioPharma Dive on July 13, 2026 3:46 PM